Highest-materiality recent filing
Enveric Biosciences upsizes ATM offering by $2.425M; prior sales total $4.48M
Filed prospectus supplement to sell up to $2,425,000 of common stock under existing ATM agreement.
Enveric Biosciences releases Q2 2026 investor presentation; no specific updates
Investor presentation made available on June 8, 2026 via company website.
Enveric shareholders approve reverse stock split, reject increase in authorized shares
Reverse stock split (1:5 to 1:15) approved: 793,344 for, 190,175 against, 8,309 abstentions.
Enveric Biosciences Q1 net loss narrows to $1.6M; cash position improved to $10.3M
Net loss $1.6M ($1.08 loss per share) vs $2.2M ($14.58) in Q1 2025; cash $4.9M at March 31.
Enveric corrects proxy error: reverse split ratio range is 1-for-5 to 1-for-15, not 1-for-50
Corrected reverse split range from erroneously stated 1-for-50 to correct 1-for-15 in proxy statement.
Enveric closes $5M private placement of shares and warrants with potential $8.9M additional proceeds
Gross proceeds of ~$5M from sale of 2.22M shares/pre-funded warrants; potential $8.9M more if warrants exercised.
Enveric Biosciences reports Q4 2025 net loss of $4.0M, cash $4.7M, advances EB-003 towards IND
Net loss of $4.0M in Q4 2025 ($6.12 per share) vs $3.2M loss ($58.06 per share) in Q4 2024; per-share impacted by 1:12 reverse split.
Enveric Biosciences registers additional $1.346M in shares under ATM facility
Filed prospectus supplement to register additional $1,346,000 of common stock under ATM agreement dated April 9, 2025.
Enveric Biosciences raises ~$1.5M in registered direct offering with warrants
Sold 328,802 shares at $4.41 per share in a registered direct offering, gross proceeds ~$1.5M.
Enveric Biosciences releases investor presentation; no key figures disclosed in filing
Investor presentation furnished on Jan 9, 2026, for use with investors, analysts, and partners.
Enveric Biosciences raises $3.1M via warrant exercise inducement at $7.05 per share
Gross proceeds of ~$3.1M from cash exercise of 426,390 existing warrants at reduced price of $7.05/sh.
Enveric shareholders approve 50x increase in authorized shares and reverse split authority
Approved increase in authorized common shares from 100M to 5B (50x) at board discretion.
Enveric Biosciences Q3 net loss $3.4M, cash $3.8M; EB-003 advances toward IND 2026
Net loss of $3.4M ($10.81 per share) in Q3 2025 vs $2.1M ($43.10) in Q3 2024; cash $3.8M as of Sept 30, 2025.
Enveric regains Nasdaq minimum bid price compliance; delisting risk removed
Received Nasdaq letter on Nov 12, 2025 confirming compliance with Listing Rule 5550(a)(2).
Enveric Biosciences announces 1-for-12 reverse stock split to address Nasdaq bid-price deficiency
Reverse split effective 8:00 a.m. ET on October 28, 2025; shares outstanding to drop from 6,219,568 to ~518,297.
Enveric raises $2.2M in warrant exercise inducement; issues new Series C/D warrants
Holders exercised 1,212,499 Series A and 1,212,499 Series B warrants at reduced price of $0.915/share.
Enveric Biosciences moves HQ to Cambridge, MA; advances EB-003 toward IND in 2026
Effective Sept 2, 2025, principal executive offices changed to 245 First Street, 18th Floor, Cambridge, MA 02142.
Enveric Biosciences receives Nasdaq deficiency notice for failing minimum equity requirement
Nasdaq notified Enveric on Aug 26, 2025 that stockholders' equity of $2.18M as of June 30, 2025 is below $2.5M minimum.
Enveric Biosciences files 8-K for investor presentation; no specific facts in filing
Management will release a Q3 2025 investor presentation on the company's website on or about Aug 29, 2025.
Enveric Biosciences Q2 net loss $2.5M; EB-003 dual mechanism disclosed, IND on track for early 2026
Net loss $2.5M ($0.97/shr) vs $1.9M ($3.72/shr) in Q2 2024; cash $2.8M at June 30.
Enveric stockholders approve conditional reverse stock split to avoid Nasdaq delisting
Stockholders authorized board to implement reverse stock split between 1:5 and 1:50 if Nasdaq issues bid price delisting determination before Jan 28, 2026.
Enveric Biosciences Q1 net loss narrows to $2.2M; progresses EB-003 IND timeline
Net loss $2.2M in Q1 2025 vs $2.5M in Q1 2024; diluted loss per share $1.22 vs $9.21.
Enveric Biosciences dismisses Marcum LLP, engages CBIZ CPAs as new auditor effective April 14
Marcum LLP dismissed as independent auditor; CBIZ CPAs P.C. engaged effective April 14, 2025 for FY 2025.
Enveric Biosciences Q4 2024 net loss $3.2M, cash $2.2M; out-licenses up to $144M
Net loss $3.2M for Q4 2024; diluted EPS loss $4.83; cash-on-hand $2.2M.
Enveric Biosciences regains Nasdaq bid price compliance
Received notice from Nasdaq on March 4, 2025 that it complied with Listing Rule 5550(a)(2).
Enveric Biosciences files 8-K to announce investor presentation; no specifics provided
Filing reports availability of an investor presentation on company website as of Feb 26, 2025.
Enveric Biosciences closes ~$5M public offering of stock and warrants
Gross proceeds ~$5M, net ~$4.3M from sale of 1.67M shares/pre-funded, Series A & B warrants at $3.00/unit.
Enveric corrects reverse stock split effective date to January 29, 2025
Reverse stock split of 1-for-15 will begin trading on Nasdaq Capital Market on January 29, 2025 (previously January 27).
Enveric Biosciences announces 1-for-15 reverse stock split effective Jan 27, 2025
Shareholders approved reverse split at a special meeting on Jan 17, 2025; ratio range 1:10 to 1:100.
Enveric Biosciences furnishes Q1 2025 investor presentation; content not detailed in filing
Presentation posted on company website on January 3, 2025.
Enveric Biosciences receives Nasdaq delisting notice on Nov 20 for bid price failure
Nasdaq notified Enveric on Nov 20, 2024, that it failed to meet the $1.00 minimum bid price requirement by the Nov 12 compliance deadline.
Enveric Biosciences Q3 net loss narrows to $2.1M; advances EB-003
Net loss of $2.1M ($0.24/share) vs $2.8M ($1.30/share) a year ago; cash $3.1M.
Enveric out-licenses EB-002 to MycoMedica for up to $62M milestones plus royalties
Exclusive global license for EB-002 (EVM201) to treat neuropsychiatric disorders.
Filing under Item 7.01 furnishes investor presentation (Exhibit 99.1) released on website on August 22, 2024 at 8:00 AM ET.
Enveric Biosciences reports Q2 2024 net loss of $1.7M; prioritizes EB-003 as lead candidate
Net loss of $1.7M ($0.23/share) vs $6.4M loss in Q2 2023; cash on hand $3.5M.
Enveric licenses radiation dermatitis product to Aries; eligible for up to $61M in milestones
Akos (Enveric sub) grants Aries exclusive worldwide license for patented radiation dermatitis topical.
All six director nominees elected; Michael D. Webb received 767,013 for, 107,751 withheld.
Enveric Biosciences regains Nasdaq equity compliance; bid price deficiency remains
Received Nasdaq letter on May 21, 2024 confirming compliance with minimum stockholders' equity requirement.
Enveric Biosciences receives Nasdaq delisting notice for bid price below $1.00
Closing bid price below $1.00 for 30 consecutive business days as of May 16, 2024.
Net loss $2.46M ($0.61 per diluted share) vs $4.80M ($2.31) in Q1 2023; cash $6.36M.
Enveric issues 458K shares at $0.94 to waive equity line restriction; no proceeds
Issued 458,000 shares to institutional investors at $0.94 per share in registered direct offering.
Enveric sets May 28, 2024 Annual Meeting; stockholder proposal deadline April 8, 2024
Annual Meeting scheduled for May 28, 2024, more than 30 days after 2023 meeting held Nov 2, 2023.
Net loss $3.44M ($1.46 per share) vs $8.80M ($4.89 per share) in Q4 2022.
Two non-binding term sheets with undisclosed biotech to out-license cannabinoid-COX-2 conjugates for joint disease (osteoarthritis, rheumatoid arthritis).
Enveric issues 228,690 shares for waiver of variable-rate limitation, enabling ATM facility
Issued 228,690 common shares at $1.41/share to institutional investors; no proceeds to Enveric.
Three non-binding term sheets signed with undisclosed biotech for exclusive global out-licenses of three compound classes.
ENVB unveils library of 57+ preclinical compounds targeting mental health disorders
Library spans 7 molecule classes including SNDRIs, NSRIs, MDMA derivatives, psilocin prodrugs, and melatonin agonists.
Enveric Biosciences gets Nasdaq extension to meet $2.5M equity requirement by May 20, 2024
Nasdaq granted extension to May 20, 2024 to meet minimum $2,500,000 stockholders' equity requirement.
Enveric Biosciences cuts 50% of workforce (7 positions) to reduce costs
Approximately 7 positions eliminated, representing ~50% of global workforce, to streamline operations.
Enveric corrects EB-003 binding affinity data, shows 1000x greater potency than previously reported
EB-003 exhibits 5-HT2A partial agonism with Ki of 0.2 µM (corrected from 0.2 mM) – 1000x higher binding affinity.
the Company terminated the employment contract of Mr. Kanubaddi without Cause (as defined in the Employment Agreement), the President and Chief Operating Officer of the Company, to be effective June 17, 2023
On February 22, 2023, Kevin M. Coveney, 59, was appointed as the chief financial officer of Enveric Biosciences, Inc. (the “Company”) effective March 13, 2023 (the “Effective Date”).
Effective as of the Effective Date, Robert Dickey IV will resign from his position as the Company’s chief financial officer.
On September 9, 2022, Robert Dickey IV was appointed as the Chief Financial Officer (“CFO”) of the Company, to serve on an interim basis, effective September 9, 2022.
On July 13, 2022, Frank Pasqualone was appointed to the board of directors (the “Board”) of Enveric Biosciences, Inc. (the “Company”), to serve as a director of the Board, to fill a vacancy as a result of the increase in the size of the Board from eight to nine persons, effective as of the same date
On June 13, 2022, Mike Webb and Bevin O’Neil were appointed to the board of directors (the “Board”) of Enveric Biosciences, Inc.
On June 13, 2022, Mike Webb and Bevin O’Neil were appointed to the board of directors (the “Board”) of Enveric Biosciences, Inc.
On May 3, 2022, Brad Thompson, PhD resigned from the board of directors (the “ Board ”) of Enveric Biosciences, Inc. (the “ Company ”).
On November 15, 2021, Enveric Biosciences, Inc. (the “Company”) appointed Avani Kanubaddi, the Chief Operating Officer of the Company, to serve as the Company’s President, effective as of November 15, 2021.
the Company appointed each of (i) Dr. Tucker, 53, (ii) Dr. Peter Facchini, 58 and (iii) Dr. Jillian Hagel, 43, to be Chief Executive Officer, Chief Scientific Officer and Chief Technology Officer, respectively
the Company appointed each of (i) Dr. Joseph Tucker, who served as president and chief executive officer, and as a director, of MagicMed immediately prior to the Effective Time and (ii) Brad Thompson, who served as a director of MagicMed immediately prior to the Effective Time, to the Company’s board of directors
assigned David Johnson, 63, the title of Executive Chairman of the Company, and removed the title of Chief Executive Officer.
Max materiality 0.85 · Median 0.57 · Most common event other_material